HTL Biotechnology is a French biotech company and world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a wide range of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force for innovation in the sector, collaborating with research entities and biotech companies to address tomorrow’s medical needs (regenerative medicine, drug delivery, etc.). HTL Biotechnology is a fast-growing international company, exporting nearly 80% of its production to over 30 countries. To meet these growing global needs for biopolymers, HTL Biotechnology has also established subsidiaries in Singapore and the United States, including the construction of a production unit for a neuromodulator. Historically based in Javené (Brittany), the company consolidates production, innovation, research and development, and quality activities on-site. HTL Biotechnology employs nearly 300 collaborators worldwide.

Biopolymers are at the heart of today’s and tomorrow’s therapeutic innovations, HTL Biotechnology offers:

Today’s portfolio: pharmaceutical-grade hyaluronic acid, PN & PDRN, cosmetic-grade sodium DNA

Quality is essential, and HTL guarantees that all its products comply with the highest quality standards and good manufacturing practices (GMP-compliant). Our commitment to safety and excellence is proven: no batch recalls in three decades, auditing and certification by regulatory bodies such as the FDA (USA). – Innovation portfolio: heparosan, oligo-HA – Biopolymer platform service: HTL offers expert advice and support to companies wishing to embark on the industrial production of a modified hyaluronic acid compound.

–  Therapeutic areas: Ophthalmology, Dermatology, Medical Aesthetics, Rheumatology

–  Based in: Javené (FRANCE) Subsidiary : HTL BMI based in Massachusetts (US)

–  Employees: 201 – 500

– Created in: 1992